Walleye Capital’s C4 Therapeutics CCCC Stock Holding History

Walleye Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$538K	Sell	115,125 -123,993	-52%	-$424K	﹤0.01%	2656
2026 Q1	$629K	Sell	239,118 -204,223	-46%	-$481K	﹤0.01%	2478
2025 Q4	$847K	Buy	+443,341	New	+$1.05M	﹤0.01%	2577
2025 Q1	–	Sell	-40,819	Closed	-$147K	–	4318
2024 Q4	$147K	Buy	+40,819	New	+$203K	﹤0.01%	3938
2024 Q3	–	Sell	-39,976	Closed	-$185K	–	5335
2024 Q2	$185K	Sell	39,976 -12,328	-24%	-$73.5K	﹤0.01%	4364
2024 Q1	$427K	Buy	+52,304	New	+$405K	﹤0.01%	3335
2023 Q2	–	Sell	-29,792	Closed	-$93.5K	–	4365
2023 Q1	$93.5K	Sell	29,792 -12,945	-30%	-$76.2K	﹤0.01%	2968
2022 Q4	$252K	Sell	42,737 -67,873	-61%	-$563K	﹤0.01%	1899
2022 Q3	$970K	Sell	110,610 -203,656	-65%	-$2.11M	0.02%	996
2022 Q2	$2.37M	Buy	+314,266	New	+$2.77M	0.07%	315
2022 Q1	–	Sell	-81,720	Closed	-$2.63M	–	2314
2021 Q4	$2.63M	Buy	+81,720	New	+$3.23M	0.08%	265

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's CCCC Position: Q2 2026 in Review

Walleye Capital reduced its C4 Therapeutics (CCCC) stake by 52% in Q2 2026, selling an estimated $424K and leaving 115,125 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.63M in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Walleye Capital held 115,125 shares of C4 Therapeutics worth $538K as of Q2 2026.
Walleye Capital sold 123,993 C4 Therapeutics shares in Q2 2026, an estimated $424K.
C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2656 holding.
Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 11 quarters since.
Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.